The Efficacy and Safety of Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma:Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study
Latest Information Update: 03 Jan 2025
At a glance
- Drugs Capecitabine (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Dec 2024 Planned End Date changed from 28 Apr 2029 to 20 Dec 2027.
- 30 Dec 2024 Planned primary completion date changed from 28 Apr 2026 to 20 Dec 2027.
- 30 Dec 2024 Status changed from recruiting to active, no longer recruiting.